Peyman Habibi

• Vector Design and Cloning: Proficiently designed expression vectors tailored for different protein production needs.
• E. coli Transformation: Demonstrated an exceptional ability to transform E. coli strains for recombinant protein expression. Optimized transformation protocols to enhance expression yields and maintain the integrity of genetic constructs.
• Protein Expression: Spearheaded the expression of diverse proteins in E. coli systems. Engineered robust expression conditions and improved fermentation strategies, resulting in increased protein yield.
• Innovative Protein Purification: Developed novel protein purification methods to streamline and improve the recovery and purity of proteins expressed in E. coli systems. Employed chromatography, affinity purification, and various other techniques to obtain high-quality protein products.
• Quality Control: Implemented stringent quality control measures to ensure the consistency and integrity of protein samples. Employed analytical techniques, including SDS-PAGE and ELISA and western blot, to verify protein quality and validate purification processes.
• Conducted experiments in laboratory environment for product development purposes.
• Trained new employees on areas of technical expertise and compliance issues relevant to lab setting.
• Reviewed technical and professional publications and journals to stay current on recent literature and make more strategic research decisions.

• Technical leadership on cross functional project teams
• Advancing an already established adherent and suspension mammalian cell culture-based platform to attain quality-driven upstream processes for improved yield and quality of rAAV-based gene delivery vector
• Improvement of the yield of AAV5 gene delivery vectors in an HEK293T platform-based process, validated at 1L, iCELLis Nano bioreactor scale, via optimization of different factors including DNA concentration, PEI/DNA particle size
• Improved MSC cell density via media optimization for large scale production via Quantum system and studied the effect of different growth media on MSCs cells differentiation
• Oversee and manage overall day-to-day lab operations
• Implement solutions to technical issues and participate in continuous improvement activities
• Support the authorship and technical review of reports, SOPs, batch records
• Collate, analyze, and present data in internal and client-facing meetings
• Supervise 7 engineers, scientists, and research associates and senior scientist.
• Conducted performance reviews and participated in hiring process of new employees.

• Vector Design and Cloning
• E. coli Transformation
• Protein Expression
• Protein purification in E.coli via AKTA system
• Antibody-Drug Conjugation (VcMMAE, VcMMAF, DM1), Click-Chemistry & Chemical Conjugations (Tetrazine, Azide, DBCO), Oligonucleotide Conjugations, Surface Immobilization, Epitope Tag, Biotin Conjugations, product development, assay/kit development, protein purification, quality control, and validation
• Improved production yield and final product quality of oYo-Link by 2 fold via an optimization of downstream process.

• Production and purification of recombinant CAS9-REV protein via E.coli system for prime editing of oIL2RB
• Development of a bioreactor to optimize CAR T cell lentiviral transduction and activation
• Assessment of the levels of soluble ACE2 protein, its enzymatic activity, and the cleavage product Ang1-7 in plasma of COVID-19 patients
• Examining ACE2 activity as a marker of renin-angiotensin system dysregulation in patients with COVID-19 disease

• Assessment of the levels of soluble ACE2 protein, its enzymatic activity, and the cleavage product Ang1-7 in plasma of COVID-19 patients. I lead a project that aimed to explore soluble ACE2, its enzymatic activity, the mechanism of interaction of soluble ACE2 (sACE2) with the spike protein, the ability to bind alternate cell receptors and the effects hydroxychloroquine (HCQ) on these ligand-receptor interactions. We further evaluated the impact of HCQ on ACE2 in plasma samples obtained in clinical trial with a small cohort of seven COVID-19 patients admitted to the hospital, treated with HCQ (NCT04329923)

• Large scale production of recombinant ACE2 by chloroplast technology and E.coli system
• Down stream processing of recombinant ACE2 and Ang1-7

• Liaised with supervisor to review grants and manuscripts to develop potential publications.
• Leveraged interpersonal and communication skills to mentor PhD, graduate and undergraduate students.
• Contributed to and actively participated in research conception, design and execution to address defined problems.
• Pursued independent and complementary research interests.
• Authored professional scientific papers for publishing in peer-reviewed journals.

• Performed culture processes using 100L bioreactor
• Led to improve the expression level of recombinant protein Interferon beta-1b via optimization of media and PH.
• Performed complex troubleshooting and assisted in leading initiatives to solve challenging scientific problems with assays or instrumentation.
• Trained new employees on areas of technical expertise and compliance issues relevant to lab setting.
• Conducted moderately complex analysis to support process development.
• Read literature related to scientific area of expertise to remain current in knowledge.